Oncology is recognised as a challenging area to forecast. This is evidenced through a 2013 study which looked at over 1700 forecasts of 260 drugs. It concluded that oncology therapies are the most commonly underestimated forecasts.
The Oncology market is expected to exceed $147 billion in 2021.
The increased importance of forecasting has become even more relevant in recent years, due to the specificity of new-era targeted therapies. These therapies target specific subsets of patients, meaning it is paramount to ensure accurate and robust forecasting to limit over-or under-estimation of product usage.